Genelux Corporation/$GNLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Ticker
$GNLX
Sector
Primary listing
Employees
26
Headquarters
Website
GNLX Metrics
BasicAdvanced
$122m
-
-$0.86
0.13
-
Price and volume
Market cap
$122m
Beta
0.13
52-week high
$8.54
52-week low
$2.26
Average daily volume
220k
Financial strength
Current ratio
2.431
Quick ratio
2.345
Long term debt to equity
10.897
Total debt to equity
14.596
Profitability
EBITDA (TTM)
-32.97
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-401,812.50%
Operating margin (TTM)
-415,175.00%
Management effectiveness
Return on assets (TTM)
-77.25%
Return on equity (TTM)
-170.00%
Valuation
Price to revenue (TTM)
12,744.186
Price to book
8.95
Price to tangible book (TTM)
8.95
Price to free cash flow (TTM)
-3.863
Free cash flow yield (TTM)
-25.88%
Free cash flow per share (TTM)
-0.709
Growth
Earnings per share change (TTM)
-8.96%
3-year revenue growth (CAGR)
-91.03%
3-year earnings per share growth (CAGR)
14.82%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genelux Corporation stock?
Genelux Corporation (GNLX) has a market cap of $122M as of May 03, 2026.
What is the P/E ratio for Genelux Corporation stock?
The price to earnings (P/E) ratio for Genelux Corporation (GNLX) stock is 0 as of May 03, 2026.
Does Genelux Corporation stock pay dividends?
No, Genelux Corporation (GNLX) stock does not pay dividends to its shareholders as of May 03, 2026.
When is the next Genelux Corporation dividend payment date?
Genelux Corporation (GNLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Genelux Corporation?
Genelux Corporation (GNLX) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.